Brief: Caplin Point Laboratories Says Unit Gets USFDA Approval For Cisatracurium Besylate Injection
12/06/2023 10:02
June 12 (Reuters) - Caplin Point Laboratories Ltd
CAPL.NS :
* UNIT CAPLIN STERILES GETS USFDA APPROVAL FOR CISATRACURIUM
BESYLATE INJECTION
Source text for Eikon: ID:nBSE9sGRQS
Further company coverage: CAPL.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Caplin Point Laboratories
See all newsBrief: Caplin Point Laboratories Says US FDA Completes Unannounced Inspection Of Caplin Steriles Gummidipoondi Facility
Brief: Caplin Point Laboratories March-Quarter Consol Net Profit 1.7 Bln Rupees
Brief: Caplin Point Laboratories Unit Receives Final USFDA Approval For ANDA Potassium Phosphates Injection
Brief: Caplin Point Laboratories Says Unit Receives USFDA Approval For Sodium Phosphates Injection
Brief: Caplin Point Laboratories Dec-Quarter Consol Net Profit 1.64 Billion Rupees